Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, October 14th. The stock was sold at an average price of $63.02, for a total transaction of $1,260,400.00. Following the sale, the chief executive officer now directly owns 480,632 shares of the company’s stock, valued at approximately $30,289,428.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) opened at 62.14 on Wednesday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $46.52 and a 12 month high of $117.12. The stock’s 50 day moving average is $69.77 and its 200-day moving average is $64.55. The company’s market capitalization is $2.45 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.02. During the same period in the prior year, the company earned ($0.83) EPS. On average, analysts expect that Ultragenyx Pharmaceutical Inc. will post ($5.96) EPS for the current year.

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Several research firms have recently weighed in on RARE. Jefferies Group reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Sunday, July 17th. Leerink Swann reissued a “buy” rating and issued a $85.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, July 15th. Cowen and Company reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 9th. Credit Suisse Group AG reissued a “buy” rating and issued a $101.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 9th. Finally, Canaccord Genuity set a $120.00 price target on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a report on Tuesday, September 20th. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $98.25.

Hedge funds have recently modified their holdings of the company. Wellington Management Group LLP increased its stake in shares of Ultragenyx Pharmaceutical by 79.9% in the first quarter. Wellington Management Group LLP now owns 4,132,430 shares of the biopharmaceutical company’s stock worth $261,625,000 after buying an additional 1,835,196 shares during the period. State Street Corp increased its position in shares of Ultragenyx Pharmaceutical by 30.6% in the first quarter. State Street Corp now owns 1,284,324 shares of the biopharmaceutical company’s stock valued at $81,315,000 after buying an additional 300,901 shares during the last quarter. Pictet Asset Management Ltd. increased its position in shares of Ultragenyx Pharmaceutical by 2,459.6% in the second quarter. Pictet Asset Management Ltd. now owns 194,527 shares of the biopharmaceutical company’s stock valued at $14,220,000 after buying an additional 186,927 shares during the last quarter. Lord Abbett & CO. LLC increased its position in shares of Ultragenyx Pharmaceutical by 116.3% in the second quarter. Lord Abbett & CO. LLC now owns 337,153 shares of the biopharmaceutical company’s stock valued at $16,490,000 after buying an additional 181,270 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in shares of Ultragenyx Pharmaceutical by 32.1% in the second quarter. Adage Capital Partners GP L.L.C. now owns 638,500 shares of the biopharmaceutical company’s stock valued at $31,229,000 after buying an additional 155,000 shares during the last quarter. 93.00% of the stock is owned by institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.